Monografie
Analysis of reduced Neurocalcin delta (NCALD) as a protective modifier in mouse models of Spinal Muscular Atrophy (SMA)
- Sprache
-
Englisch
- Identifier
-
1123703736
Thema
Orthopädie; Hochschulschrift
Beteiligte Personen und Organisationen
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:56 MEZ
Objekttyp
- Monografie
Beteiligte
- Kaczmarek, Anna
- Wirth, Brunhilde
Ähnliche Objekte (12)
Analysis of the modifying influence of Plastin 3 (PLS3) on Spinal Muscular Atrophy (SMA) by generation of transgenic mouse models
Combined therapie of SMN-ASO and Plastin 3 overexpression rescues severe SMA in mice
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Neurocalcin delta (NCALD) knockout impairs adult neurogenesis whereas half reduction is a safe therapeutic option for spinal muscular atrophy
Identification and functional characterization of BICD2 mutations causing SMALED2, a congenital dominant form of spinal muscular atrophy
Analyses of spinal muscular atrophy (SMA) modifiers and drug-dependent responses using motoneurons (MNs) derived from induced pluripotent stem cells (iPSCs)
Analysis and inhibition of dysregulated pathways in a mouse model of the motoneuron disease Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Diagnosis and management of spinal muscular atrophy : : Part 2
Molecular genetic investigations of histone deacetylase inhibitors as potential neurotherapeutics for autosomal recessive proximal spinal muscular atrophy (SMA)
T-plastin, a cytoskeletal protein with important function in axonal growth, acts as a modifier of spinal muscular atrophy
Analysis of the modifying influence of Plastin 3 (PLS3) on Spinal Muscular Atrophy (SMA) by generation of transgenic mouse models
Combined therapie of SMN-ASO and Plastin 3 overexpression rescues severe SMA in mice
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Neurocalcin delta (NCALD) knockout impairs adult neurogenesis whereas half reduction is a safe therapeutic option for spinal muscular atrophy
Identification and functional characterization of BICD2 mutations causing SMALED2, a congenital dominant form of spinal muscular atrophy
Analyses of spinal muscular atrophy (SMA) modifiers and drug-dependent responses using motoneurons (MNs) derived from induced pluripotent stem cells (iPSCs)
Analysis and inhibition of dysregulated pathways in a mouse model of the motoneuron disease Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Diagnosis and management of spinal muscular atrophy : : Part 2
Molecular genetic investigations of histone deacetylase inhibitors as potential neurotherapeutics for autosomal recessive proximal spinal muscular atrophy (SMA)
T-plastin, a cytoskeletal protein with important function in axonal growth, acts as a modifier of spinal muscular atrophy
Analysis of the modifying influence of Plastin 3 (PLS3) on Spinal Muscular Atrophy (SMA) by generation of transgenic mouse models
Combined therapie of SMN-ASO and Plastin 3 overexpression rescues severe SMA in mice
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Neurocalcin delta (NCALD) knockout impairs adult neurogenesis whereas half reduction is a safe therapeutic option for spinal muscular atrophy
Identification and functional characterization of BICD2 mutations causing SMALED2, a congenital dominant form of spinal muscular atrophy
Analyses of spinal muscular atrophy (SMA) modifiers and drug-dependent responses using motoneurons (MNs) derived from induced pluripotent stem cells (iPSCs)
Analysis and inhibition of dysregulated pathways in a mouse model of the motoneuron disease Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Diagnosis and management of spinal muscular atrophy : : Part 2
Molecular genetic investigations of histone deacetylase inhibitors as potential neurotherapeutics for autosomal recessive proximal spinal muscular atrophy (SMA)